The latest price target for Vistagen Therapeutics (NASDAQ:VTGN) was reported by Jefferies on December 7, 2023. The analyst firm set a price target for $15.00 expecting VTGN to rise to within 12 months (a possible 360.62% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vistagen Therapeutics (NASDAQ:VTGN) was provided by Jefferies, and Vistagen Therapeutics upgraded their buy rating.

The last upgrade for Vistagen Therapeutics Inc happened on December 7, 2023 when Jefferies raised their price target to $15. Jefferies previously had a hold for Vistagen Therapeutics Inc.

The last downgrade for Vistagen Therapeutics Inc happened on July 26, 2022 when Maxim Group changed their price target from N/A to N/A for Vistagen Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vistagen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vistagen Therapeutics was filed on December 7, 2023 so you should expect the next rating to be made available sometime around December 7, 2024.

While ratings are subjective and will change, the latest Vistagen Therapeutics (VTGN) rating was a upgraded with a price target of $0.20 to $15.00. The current price Vistagen Therapeutics (VTGN) is trading at is $3.26, which is within the analyst’s predicted range.